{"id":"W2145118120","doi":"10.1016/s1470-2045(13)70162-1","title":"Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Regional Cancer Foundation; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Celgene","keywords":"Medicine; Tolerability; Response Evaluation Criteria in Solid Tumors; Internal medicine; Regimen; Metastatic Urothelial Carcinoma; Paclitaxel; Clinical endpoint; Adverse effect; Gastroenterology; Progressive disease; Refractory (planetary science); Phases of clinical research; Oncology; Progression-free survival; Chemotherapy; Bladder cancer; Cancer; Clinical trial; Urothelial carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001726623,0.001983612,0.003127064,0.000575614,0.00054751,0.001633441,0.001092097,0.002284992,0.002535254],"category_scores_gemma":[0.001068525,0.000784411,0.0021272,0.0006090492,0.001097137,0.001236493,0.0004714931,0.002965876,0.0007589972],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001506078,"about_ca_system_score_gemma":0.001614141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002123736,"about_ca_topic_score_gemma":0.003600669,"domain_scores_codex":[0.9994184,0.0002264552,0.00001931863,0.0001424241,0.00007335661,0.0001200847],"domain_scores_gemma":[0.9993616,0.0001032397,0.0001438647,0.00007424938,0.00006290271,0.0002541677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.740908,0.08450559,0.003457671,0.00141421,0.005179639,0.0002615481,0.0005257309,0.0037364,0.07392616,0.0001987987,0.0039374,0.08194885],"study_design_scores_gemma":[0.5533999,0.42741,0.008903581,0.00003764642,0.001435649,0.0001856483,0.00009204241,0.001423576,0.005072762,0.0001278775,0.001848278,0.000062917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949322,0.001507549,0.000750343,0.0003027326,0.0001709521,0.001239406,0.0003456769,0.00009173368,0.0006594425],"genre_scores_gemma":[0.9908394,0.002015749,0.001539728,0.0008169654,0.0001869444,0.001241385,0.0009439334,0.00009016292,0.002325738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003127064,"threshold_uncertainty_score":0.01092738,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1066452464032428,"score_gpt":0.3854882551437152,"score_spread":0.2788430087404724,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}